Publicaciones en colaboración con investigadores/as de National Cancer Center Hospital (7)

2021

  1. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581

  2. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2

    Clinical Breast Cancer, Vol. 20, Núm. 2, pp. e173-e180

2016

  1. Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer [Supportive Care in Cancer, (2015), DOI:10.1007/s00520-015-2904-5]

    Supportive Care in Cancer

  2. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

    Supportive Care in Cancer, Vol. 24, Núm. 1, pp. 447-455

2015

  1. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results of NCIC CTG MA.31

    Journal of Clinical Oncology, Vol. 33, Núm. 14, pp. 1574-1583

2012

  1. Bone-related complications and quality of life in advanced breast cancer: Results from a randomized phase III trial of denosumab versus zoledronic acid

    Clinical Cancer Research, Vol. 18, Núm. 17, pp. 4841-4849